ECHO Discovery Fireside Chat: HDAX Therapeutics

Join us and the Translational Biology and Engineering Program for an ECHO Discovery Fireside Chat with Dr. Nabanita Nawar – CEO & Founder of HDAX Therapeutics!

HDAX Therapeutics is a biotechnology company pioneering a novel approach to target HDAC6 to address critical unmet medical needs in cardiometabolic, inflammatory, and select neurological diseases. Their innovative 2-site binding mechanism has the potential to deliver best-in-class HDAC6-targeting therapeutics and tackle major limitations of first generation HDAC inhibitors, such as weak binding, poor selectivity, suboptimal pharmacokinetics, and off-target toxicities.

Dr. Nawar holds a PhD in Medicinal Chemistry from the University of Toronto, where she honed her expertise in small-molecule drug discovery and HDAC6 intervention. She played a pivotal role in establishing HDAX’s foundational science, driving its corporate formation, advancing through multiple value-generating milestones, and successfully raising pre-seed and seed financing to develop next-generation small molecules addressing critical unmet clinical needs.

Register for this free, virtual chat today!

This Fireside Chat is part of the ECHO Discovery program, a foundational education program that explores ideation, research translation, and entrepreneurship.

ECHO Discovery is funded and organized by the Translational Biology & Engineering Program and TRANSFORM HF, at the University of Toronto and Ted Rogers Centre for Heart Research.